GlassScriptPhysician profile
Kendal L Hervert
NPI 1912214115
$1,583.86
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $180 · 2021: $223.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Auris Health, INC. | $280.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $166.12 | 2019-2021 | |
| Amgen INC. | $141.39 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $121.91 | 2019 | |
| Lilly USA, LLC | $107.72 | 2019 | |
| Ethicon INC. | $88.18 | 2019-2021 | |
| Seagen INC. | $87.43 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.61 | 2019 | |
| Celgene Corporation | $64.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.62 | 2020 | |
| Array Biopharma INC | $47.59 | 2019 | |
| Abbvie INC. | $36.16 | 2019-2020 | |
| Genzyme Corporation | $35.75 | 2019 | |
| Janssen Biotech, INC. | $33.00 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $32.93 | 2020-2021 | |
| Astellas Pharma US INC | $32.51 | 2021 | |
| Tesaro, INC. | $21.52 | 2019 | |
| Daiichi Sankyo INC. | $16.29 | 2020 | |
| Clovis Oncology, INC. | $15.86 | 2021 | |
| Puma Biotechnology, INC. | $14.60 | 2019 | |
| Genentech USA, INC. | $14.54 | 2019 | |
| Kyowa Kirin, INC. | $13.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.54 | 2021 | |
| Eisai INC. | $11.91 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendal Hervert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.